Tiantan Bio revises charter, reports revenue increase amid profit decline

Beijing Tiantan Biological Products Corp (SSE:600161) has announced proposed revisions to its articles of association alongside its first quarter financial results for 2025. The proposed revisions aim to modernize corporate governance practices. Key changes include clarifying the role of the legal representative, establishing an audit and risk management committee replacing the supervisory board, and updating the powers and responsibilities of board members and senior management.